SPH.WAR Sopharma AD
- Market cap
- PLN 7.70B
- P/E
- -
- P/B
- 3.14x
- ROE
- 19.3%
- Dividend yield
- 2.98%
- Fundamental score
- 2.3/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is SPH.WAR undervalued?
Graham numberThe Graham number of Sopharma AD cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sopharma AD fundamental analysis
11 of 22 checks passedROE 1/2
Moderate return on equity (19.3%), between 10% and 20%.
ROA 1/1
Return on assets (9.6%) is above the industry median (2.7%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-15.9%) is not above the 5-year average (10.4% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-15.9%) is below the industry median (1.4%).
Revenue Growth 2/2
Revenue grew 16.2% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (53.4%), up to 100%.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 1/1
EBIT is 14.3x against interest expense, well covered.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (3.1x) is above the industry median (1.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
Dividend yield cannot be calculated.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 10.2%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Sopharma AD stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sopharma AD
Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening con…
Full company profileSopharma AD financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sopharma AD annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 877M | 1.02B | 1.18B | 1.28B | 1.44B | 1.60B | 1.66B | 1.89B | 2.13B | 2.61B | 2.78B |
| Gross Profit | 220M | 252M | 267M | 302M | 303M | 341M | 357M | 416M | 454M | 604M | 680M |
| Operating Income | 45.0M | 55.8M | 39.1M | 107M | 45.8M | 89.5M | 89.6M | 98.1M | 81.8M | 146M | 211M |
| EBITDA | 101M | 90.2M | 76.2M | 144M | 90.5M | 162M | 143M | 177M | 166M | 257M | 307M |
| Net Income | 50.6M | 40.0M | 28.3M | 87.0M | 29.8M | 89.5M | 71.1M | 95.2M | 76.3M | 134M | 197M |
| EPS | 0.39 | 0.32 | 0.23 | 0.69 | 0.24 | 0.71 | 0.59 | 0.68 | 0.46 | 0.39 | 0.35 |
| Balance Sheet | |||||||||||
| Total Assets | 859M | 981M | 1.01B | 1.18B | 1.24B | 1.20B | 1.26B | 1.51B | 1.80B | 2.08B | 2.06B |
| Total Liabilities | 368M | 478M | 502M | 600M | 676M | 546M | 538M | 761M | 953M | 1.10B | 1.00B |
| Shareholders' Equity | 457M | 470M | 476M | 556M | 553M | 647M | 706M | 738M | 824M | 951M | 1.02B |
| Cash & Short-term Investments | 22.6M | 22.6M | 24.1M | 27.3M | 25.1M | 37.7M | 19.7M | 129M | 35.7M | 71.6M | 46.7M |
| Total Debt | 210M | 262M | 303M | 384M | 389M | 323M | 279M | 334M | 481M | 613M | 545M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 50.6M | 40.0M | 28.3M | -128M | -179M | -76.0M | 125M | 45.0M | 76.7M | 18.6M | 105M |
| Capital Expenditure | 18.2M | 22.5M | 27.8M | 40.0M | 27.0M | 27.1M | 23.2M | 43.3M | 121M | 143M | 57.0M |
| Free Cash Flow | 32.4M | 17.5M | 501K | -168M | -206M | -103M | 101M | 1.75M | -44.7M | -124M | 47.2M |
| Ratios | |||||||||||
| ROE | 11.1% | 8.5% | 6.0% | 15.6% | 5.4% | 13.8% | 10.1% | 12.9% | 9.3% | 14.0% | 19.3% |
| ROA | 5.9% | 4.1% | 2.8% | 7.4% | 2.4% | 7.4% | 5.7% | 6.3% | 4.2% | 6.4% | 9.6% |
| Net Profit Margin | 5.8% | 3.9% | 2.4% | 6.8% | 2.1% | 5.6% | 4.3% | 5.0% | 3.6% | 5.1% | 7.1% |
| Debt to Equity | 0.46x | 0.56x | 0.64x | 0.69x | 0.70x | 0.50x | 0.40x | 0.45x | 0.58x | 0.64x | 0.53x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sopharma AD dividends
- Dividend yield
- 2.98%
- Forward dividend
- 0.41 PLN
- Payout ratio
- 10.2%
- Ex-dividend date
- Jul 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 13.6M | 0.04 | 10.2% |
| 2024 | BGN 168M | 1.02 | 220.7% |
| 2023 | BGN 71.9M | 0.52 | 75.5% |
| 2022 | BGN 11.0K | 0.00 | 0.0% |
| 2021 | BGN 63.0K | 0.00 | 0.1% |
| 2020 | BGN 22.6M | 0.18 | 76.0% |
| 2019 | BGN 3.50M | 0.03 | 4.0% |
| 2018 | BGN 22.6M | 0.18 | 79.8% |
| 2017 | BGN 15.5M | 0.12 | 38.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 959692:319897 on Jul 10, 2025.
Who owns Sopharma AD
- Insiders 66.42%
- Institutions 0.17%
- Public & others 33.41%
- Shares outstanding 538M
- Free float 178M
Sopharma AD company profile
- Company name
- Sopharma AD
- Ticker
- SPH.WAR
- ISIN
- BG11SOSOBT18
- Exchange
- Warsaw Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 6,049
- Fiscal year end
- December
- Address
- 16, Iliensko Shousse St., Sofia, Bulgaria, 1220
- Phone
- 359 28 13 42 00
- Website
- sopharmagroup.com
About Sopharma AD
Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana, a herbal medicine to reduce the stress; veterinary vaccines; and medical devices, such as gauzes, compresses, and dressing. The company also provides food supplements; medicinal and cosmetic products, including plasters, bandages, herbal cosmetics, and sanitary-hygiene products; and yophilic products, ointments, syrups, drops, suppositories, inhalers, haemodialysis concentrates, sachets, substances, infusion solutions, veterinary vaccines, solutions and chemical substances and mixture. In addition, the company distributes pharmaceuticals, and sanitary and hygiene products; and provides contract manufacturing services, regulatory services, laboratory analysis, transport services, and other services. Further, it is involved in trading of pharmaceuticals; manufacturing medical plant; and provision of public opinion research services. Additionally, the company engages in the offline and online retail trade of medicinal products and medical equipment; and rental of properties, as well as in trading, consulting, and other activities. Sopharma AD was founded in 1933 and is headquartered in Sofia, Bulgaria.
Sopharma AD management
10- Dr. Ognian Ivanov Donev M.D., Ph.D.Chairman, CEO & MD · born 1957
- Mr. Boris Anchev BorisovCFO, Financial Director & Director
- Iordanka Nikolova PetkovaChief Accountant
- Pelagia Stefanova ViatchevaDirector of Investor Relations
- Mr. Alexandar YotovHead of Legal Department
- E. KrastevaDirector of Advertising & Corporate Communications
- Lyudmila BondzhovaHead of Reporting Department
- E. MihailovaHead of Production Division
- S. KatzarovaHead of Regulatory Affairs Bulgaria & Third Markets Division
- M. KotzevaHead of Drug Safety Department